Exosomes packaging APOBEC3G confer human immunodeficiency virus resistance to recipient cells

Atanu K. Khatua, Harry E. Taylor, James Hildreth, Waldemar Popik

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

The human cytidine deaminase APOBEC3G (A3G) is a part of a cellular defense system against human immunodeficiency virus type 1 (HIV-1) and other retroviruses. Antiretroviral activity of A3G can be severely blunted in the presence of the HIV-1 protein Vif. However, in some cells expressing the enzymatically active low-molecular-mass form of A3G, HIV-1 replication is restricted at preintegration steps, before accumulation of Vif. Here, we show that A3G can be secreted by cells in exosomes that confer resistance to both vif-defective and wild-type HIV-1 in exosome recipient cells. Our results also suggest that A3G is the major exosomal component responsible for the anti-HIV-1 activity of exosomes. However, enzymatic activity of encapsidated A3G does not correlate with the observed limited cytidine deamination in HIV-1 DNA, suggesting that A3G-laden exosomes restrict HIV-1 through a nonenzymatic mechanism. Real-time PCR quantitation demonstrated that A3G exosomes reduce accumulation of HIV-1 reverse transcription products and steady-state levels of HIV-1 Gag and Vif proteins. Our findings suggest that A3G exosomes could be developed into a novel class of anti-HIV-1 therapeutics.

Original languageEnglish (US)
Pages (from-to)512-521
Number of pages10
JournalJournal of Virology
Volume83
Issue number2
DOIs
StatePublished - Jan 2009
Externally publishedYes

Fingerprint

exosomes
Exosomes
Human immunodeficiency virus
Product Packaging
Human immunodeficiency virus 1
packaging
HIV-1
HIV
cells
Human Immunodeficiency Virus gag Gene Products
Retroviridae
Cytidine Deaminase
Human Immunodeficiency Virus Proteins
cytidine
Cytidine
deamination
Deamination
reverse transcription
Virus Replication
Reverse Transcription

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Exosomes packaging APOBEC3G confer human immunodeficiency virus resistance to recipient cells. / Khatua, Atanu K.; Taylor, Harry E.; Hildreth, James; Popik, Waldemar.

In: Journal of Virology, Vol. 83, No. 2, 01.2009, p. 512-521.

Research output: Contribution to journalArticle

Khatua, Atanu K. ; Taylor, Harry E. ; Hildreth, James ; Popik, Waldemar. / Exosomes packaging APOBEC3G confer human immunodeficiency virus resistance to recipient cells. In: Journal of Virology. 2009 ; Vol. 83, No. 2. pp. 512-521.
@article{fed86840fd404721927765c3ee48cd6b,
title = "Exosomes packaging APOBEC3G confer human immunodeficiency virus resistance to recipient cells",
abstract = "The human cytidine deaminase APOBEC3G (A3G) is a part of a cellular defense system against human immunodeficiency virus type 1 (HIV-1) and other retroviruses. Antiretroviral activity of A3G can be severely blunted in the presence of the HIV-1 protein Vif. However, in some cells expressing the enzymatically active low-molecular-mass form of A3G, HIV-1 replication is restricted at preintegration steps, before accumulation of Vif. Here, we show that A3G can be secreted by cells in exosomes that confer resistance to both vif-defective and wild-type HIV-1 in exosome recipient cells. Our results also suggest that A3G is the major exosomal component responsible for the anti-HIV-1 activity of exosomes. However, enzymatic activity of encapsidated A3G does not correlate with the observed limited cytidine deamination in HIV-1 DNA, suggesting that A3G-laden exosomes restrict HIV-1 through a nonenzymatic mechanism. Real-time PCR quantitation demonstrated that A3G exosomes reduce accumulation of HIV-1 reverse transcription products and steady-state levels of HIV-1 Gag and Vif proteins. Our findings suggest that A3G exosomes could be developed into a novel class of anti-HIV-1 therapeutics.",
author = "Khatua, {Atanu K.} and Taylor, {Harry E.} and James Hildreth and Waldemar Popik",
year = "2009",
month = "1",
doi = "10.1128/JVI.01658-08",
language = "English (US)",
volume = "83",
pages = "512--521",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - Exosomes packaging APOBEC3G confer human immunodeficiency virus resistance to recipient cells

AU - Khatua, Atanu K.

AU - Taylor, Harry E.

AU - Hildreth, James

AU - Popik, Waldemar

PY - 2009/1

Y1 - 2009/1

N2 - The human cytidine deaminase APOBEC3G (A3G) is a part of a cellular defense system against human immunodeficiency virus type 1 (HIV-1) and other retroviruses. Antiretroviral activity of A3G can be severely blunted in the presence of the HIV-1 protein Vif. However, in some cells expressing the enzymatically active low-molecular-mass form of A3G, HIV-1 replication is restricted at preintegration steps, before accumulation of Vif. Here, we show that A3G can be secreted by cells in exosomes that confer resistance to both vif-defective and wild-type HIV-1 in exosome recipient cells. Our results also suggest that A3G is the major exosomal component responsible for the anti-HIV-1 activity of exosomes. However, enzymatic activity of encapsidated A3G does not correlate with the observed limited cytidine deamination in HIV-1 DNA, suggesting that A3G-laden exosomes restrict HIV-1 through a nonenzymatic mechanism. Real-time PCR quantitation demonstrated that A3G exosomes reduce accumulation of HIV-1 reverse transcription products and steady-state levels of HIV-1 Gag and Vif proteins. Our findings suggest that A3G exosomes could be developed into a novel class of anti-HIV-1 therapeutics.

AB - The human cytidine deaminase APOBEC3G (A3G) is a part of a cellular defense system against human immunodeficiency virus type 1 (HIV-1) and other retroviruses. Antiretroviral activity of A3G can be severely blunted in the presence of the HIV-1 protein Vif. However, in some cells expressing the enzymatically active low-molecular-mass form of A3G, HIV-1 replication is restricted at preintegration steps, before accumulation of Vif. Here, we show that A3G can be secreted by cells in exosomes that confer resistance to both vif-defective and wild-type HIV-1 in exosome recipient cells. Our results also suggest that A3G is the major exosomal component responsible for the anti-HIV-1 activity of exosomes. However, enzymatic activity of encapsidated A3G does not correlate with the observed limited cytidine deamination in HIV-1 DNA, suggesting that A3G-laden exosomes restrict HIV-1 through a nonenzymatic mechanism. Real-time PCR quantitation demonstrated that A3G exosomes reduce accumulation of HIV-1 reverse transcription products and steady-state levels of HIV-1 Gag and Vif proteins. Our findings suggest that A3G exosomes could be developed into a novel class of anti-HIV-1 therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=58149517753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149517753&partnerID=8YFLogxK

U2 - 10.1128/JVI.01658-08

DO - 10.1128/JVI.01658-08

M3 - Article

VL - 83

SP - 512

EP - 521

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 2

ER -